Skip to main content

Table 3 Baseline data of the enrolled patients

From: Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis

Study

Sample size

Age (years)

F/M

MELD score

Total bilirubin (mg/dl)

Child-Pugh score

Creatinine (mg/dl)

pH

Serum ionized calcium (mmol/l)

Schultheiss et al. [9]

28

57 ± 11

8/20

36 ± 8.8

12 ± 14.7

12 ± 2.2

3.4 ± 2.0

7.29 ± 0.1

1.21 ± 0.08

Lahmer et al. [10]

24

59

4/20

35 ± 6.5

18.4 ± 14.5

≥ 10

3.8 ± 1.2

7.29 ± 0.05

1.14 ± 0.11

Slowinski et al. [11]

133

63 ± 15

38/95

NR

7.3

NR

2.8 ± 1.35

7.33

1.08 ± 0.12

Sponholz et al. [18]

89

54 ± 9.6

31/58

NR

7 ± 7.4

NR

2 ± 1.0

7.39 ± 0.07

1.11 ± 0.11

Durao et al. [19]

143

66 ± 16

59/84

NR

NR

NR

1.5 ± 0.88

7.29 ± 0.11

1.06 ± 0.06

De Vico et al. [20]

15

67.4 ± 11.9

5/10

NR

3.1 ± 3.38

NR

1.97 ± 0.88

7.38 ± 0.09

1.02 ± 0.06

Saner et al. [21]

68

47.1 ± 11.8

28/40

23.1 ± 9.1

8.7 ± 8.1

NR

2.35 ± 1.01

7.37 ± 0.08

1.08 ± 0.03

Balogun et al. [22]

697

56.4

281/416

17.7–44.81

11.4

NR

≥ 4

NR

NR

Klingele et al. [23]

69

59.1 ± 12.4

22/47

19.7 ± 9.6

9.5 ± 10.6

NR

2.7 ± 1.3

NR

NR

Yu et al. [24]

145

59 ± 17.7

92/53

NR

NR

NR

2.7 ± 3

NR

NR

Summarized

1411

57.9

568/843

25.2 ± 10.8

10.5

Grade C

2.44 ± 1.77

7.33 ± 0.1

1.08 ± 0.07

  1. Abbreviations: F female, M male, MELD model of end-stage liver disease, NR not reported